Journal of Comparative Effectiveness Research: 2023, vol: , issue:
1)- Jeffrey Frankel, David Staskin, Susann Varano, Diane K Newman, Steven G Gregg, Janet Owens-Grillo. Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?Journal of comparative effectiveness research. 2023, 12 (9): CER
2)- David Staskin, Jeffrey Frankel, Steven G Gregg, Susann Varano, Janet Owens-Grillo. Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study.Journal of comparative effectiveness research. 2023, 12 (9): CER
3)- Virender Bhan, Fraser Clift, Moogeh Baharnoori, Kimberly Thomas, Barkha P Patel, François Blanchette, Nicholas Adlard, Umakanth Vudumula, Kapil Gudala, Nikkita Dutta, Daniel Grima, Soukaïna Mouallif, Fatine Farhane. Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.Journal of comparative effectiveness research. 2023, 12 (9): e220175
4)- Jose Osorio, Sonia Maccioni, Reecha Sharma, Leena Patel, Paul Spin, Andrea Natale. QDOT MICRO™ versus THERMOCOOL SMARTTOUCH™ and THERMOCOOL SMARTTOUCH Surround Flow in radiofrequency ablation of paroxysmal atrial fibrillation.Journal of comparative effectiveness research. 2023, 12 (9): e230005
5)- Teri J Mauch, Michael R Chladek, Spero Cataland, Shruti Chaturvedi, Bradley P Dixon, Katherine Garlo, Christoph Gasteyger, Anuja Java, Jorge Leguizamo, Lucy Lloyd-Price, Tan P Pham, Tara Symonds, Ioannis Tomazos, Yan Wang. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome.Journal of comparative effectiveness research. 2023, 12 (9): e230036
6)- Aaron T Gerds, Claudia Castro, Frank Snopek, Megan M Flynn, Alexandra G Ellis, Meredith Manning, Ray Urbanski. Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.Journal of comparative effectiveness research. 2023, 12 (9): e230066
7)- Joel Iff, Yi Zhong, Edward Tuttle, Deepshekhar Gupta, Xander Paul, Erik Henricson. Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA.Journal of comparative effectiveness research. 2023, 12 (9): e230086
8)- Sreeram V Ramagopalan, Catrin Treharne, Jonathan Pearson-Stuttard, Vivek Subbiah. For what it's worth: the complex area of medicine value assessment.Journal of comparative effectiveness research. 2023, 12 (9): e230120
9)- Marissa Betts, Kyle Fahrbach, Binod Neupane, Mahmoud Slim, Maria Pia Sormani, Gary Cutter, Thomas Pa Debray, Marvin Rock. Handling related publications reporting real-world evidence in network meta-analysis: a case study in multiple sclerosis.Journal of comparative effectiveness research. 2023, 12 (8): e220132
10)- Jie He, Yuanyuan Gao, Ge Bai, Jie Wang, Yongshun Sun. Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis.Journal of comparative effectiveness research. 2023, 12 (8): e220165
11)- Svenja Petersohn, Bradley McGregor, Sven L Klijn, Jessica R May, Flavia Ejzykowicz, Murat Kurt, Matthew Dyer, Bill Malcolm, Sébastien Branchoux, Katharina Nickel, Saby George, Sonja Kroep. Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma.Journal of comparative effectiveness research. 2023, 12 (8): e230004
12)- Josep Comín Colet, Antoni Sicras Mainar, Joel Salazar-Mendiguchía, María Isabel Del Campo Alonso, Ainara Echeto, David Vilanova Larena, Olga Delgado Sánchez. Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol.Journal of comparative effectiveness research. 2023, 12 (8): e230007
13)- Petra Stazić, Diana Jurić, Antonela Turić, Antonio Šošić, Ana Marušić, Marija Roguljić. Reporting characteristics of nonsurgical periodontal therapy trials registered in ClinicalTrials.gov: an observational study.Journal of comparative effectiveness research. 2023, 12 (8): e230058
14)- Jennifer Ken-Opurum, Sesha Ss Srinivas, Seojin Park, Scott Charland, Andrew Revel, Ronald Preblick. Clinical and economic outcomes associated with use of anti-arrhythmic drugs versus ablation in atrial fibrillation.Journal of comparative effectiveness research. 2023, 12 (8): e230065
15)- Ayman Al-Hendy, Andrea S Lukes, Roberta Venturella, Claudio Villarroel, Laura McKain, Yulan Li, Rachel B Wagman, Elizabeth A Stewart. A plain language summary of the long-term relugolix combination therapy study for uterine fibroids.Journal of comparative effectiveness research. 2023, 12 (8): e230069
16)- David Vizcaya, Csaba P Kovesdy, Andrés Reyes, Elena Pessina, Pau Pujol, Glen James, Nikolaus G Oberprieler. Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study.Journal of comparative effectiveness research. 2023, 12 (8): e230076
17)- Yanni Hao, Wei-Chun Hsu, Craig S Parzynski, Evgeny Degtyarev, Lisa V Hampson, Aisha Masood, Wen-Hsing Wu. Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma.Journal of comparative effectiveness research. 2023, 12 (7): e220173
18)- Samer Haidar, Reynaldo Vazquez, Goran Medic. Impact of surgical complications on hospital costs and revenues: retrospective database study of Medicare claims.Journal of comparative effectiveness research. 2023, 12 (7): e230080
19)- Ana Paula Beck da Silva Etges, Luciana Rodrigues de Lara, Stella Lisboa Sapper, Ana Von Frankenberg Berger, Melissa Streck, Laise Zardo, Armani Linhares, Marina Nassif, Angélica Zanotto, Marta Nassif Pereira Lima, Rafael Vargas, Carisi Anne Polanczyk. Redesign of radiotherapy for prostate cancer: a proposal for universal healthcare systems.Journal of comparative effectiveness research. 2023, 12 (12): e230023
20)- Chandler Long, Abimbola O Williams, Caroline M Jacobsen, Alysha M McGovern, Liesl M Hargens, Sue Duval, Michael R Jaff. Diversity in clinical trial inclusion for peripheral artery disease lower extremity endovascular interventions: a systematic review protocol.Journal of comparative effectiveness research. 2023, 12 (12): e230048
21)- Jun Ma, Donglu Zhao, Bihong Zhen, Yan Xia, Qianyi Gong, Wendong Chen. Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma.Journal of comparative effectiveness research. 2023, 12 (12): e230073
22)- Thomas Roth, Michael J Thorpy, Clete A Kushida, Matthew Horsnell, Jennifer Gudeman. Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary.Journal of comparative effectiveness research. 2023, 12 (12): e230133
23)- Amnon Ariel, Peter J Barnes, Tiago Maricoto, Miguel Román-Rodríguez, Andy Powell, Jennifer K Quint. Rational use of inhaled corticosteroids for the treatment of COPD: a plain language summary.Journal of comparative effectiveness research. 2023, 12 (12): e230136
24)- Steven D Pearson, Prabhjot Singh, Francesca Beaudoin, Jon Campbell, Lindsey Schapiro, Sarah K Emond, Caroline Pearson. Institute for Clinical and Economic Review - Peterson Health Technology Institute value assessment framework for digital health technologies.Journal of comparative effectiveness research. 2023, 12 (12): e230154
25)- Ethan Basch, Kathryn Hudson, Gabrielle Rocque. Implementation of electronic patient-reported outcomes for symptom monitoring during cancer treatment: the importance of getting it right.Journal of comparative effectiveness research. 2023, 12 (12): e230157
26)- Alice Beattie, Catrin Treharne, Silvy Mardiguian, Sreeram V Ramagopalan. Access in all areas? A round up of developments in market access and health technology assessment: part 2.Journal of comparative effectiveness research. 2023, 12 (12): e230162
27)- Amy Keith, Timothy C Jenkins, Sonja O'Leary, Amy B Stein, Sophie E Katz, Jason Newland, Deborah J Rinehart, Aiden Gilbert, Sherry Dodd, Cindy M Terrill, Holly M Frost. Reducing length of antibiotics for children with ear infections: protocol for a cluster-randomized trial in the USA.Journal of comparative effectiveness research. 2023, 12 (11): e230088
28)- George Hale, James Morris, Jules Barker-Yip. Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.Journal of comparative effectiveness research. 2023, 12 (11): e230093
29)- Jon Apple, Maral DerSarkissian, Anne Shah, Rose Chang, Yan Chen, Xuanhao He, Justin Chun. Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs.Journal of comparative effectiveness research. 2023, 12 (11): e230107
30)- Enrique Casado, José Rosas, Carlos Rubio-Terrés, Darío Rubio-Rodríguez, Mitra Boolell, Ignacio Arístegui. Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain.Journal of comparative effectiveness research. 2023, 12 (11): e230115
32)- Ashley Jaksa, Patrick J Arena, Nicolle Gatto. Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations.Journal of comparative effectiveness research. 2023, 12 (11): e230125
33)- Stephen Duffield, Páll Jónsson. The real-world impact of National Institute for Health and Care Excellence's real-world evidence framework.Journal of comparative effectiveness research. 2023, 12 (11): e230135
34)- Benjamin D Bray, Sreeram V Ramagopalan. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 13.Journal of comparative effectiveness research. 2023, 12 (11): e230141
35)- Elisa M Amoroso. Regional differences in the utilization and outcomes of cerebral embolic protection during transcatheter aortic valve replacement: an analysis of the National Inpatient Sample from 2017 through 2019.Journal of comparative effectiveness research. 2023, 12 (10): e230010
36)- Neil Hawkins, Noemi Muszbek, Rachel Evans, Linda McNamara, Trefor Jones. Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.Journal of comparative effectiveness research. 2023, 12 (10): e230017
37)- Andreas Freitag, Laura Gurskyte, Grammati Sarri. Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations.Journal of comparative effectiveness research. 2023, 12 (10): e230046
38)- Jesse Fishman, Koo Wilson, Aleksandra Drzewiecka, Michał Pochopień, David Dingli. The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA.Journal of comparative effectiveness research. 2023, 12 (10): e230055
39)- Jessie T Yan, Devon J Boyne, Ernest Lo, Eliya Farah, Dylan E O'Sullivan, Winson Y Cheung. Real-world impact of patient-reported outcome measurement on overall survival, healthcare use and treatment discontinuation in cancer patients.Journal of comparative effectiveness research. 2023, 12 (10): e230061
40)- Hamza Alshannaq, John J Isitt, Richard F Pollock, Gregory J Norman, Greg Cogswell, Peter M Lynch, Stéphane Roze. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada.Journal of comparative effectiveness research. 2023, 12 (10): e230075
41)- Caroline Pearson, Lindsey Schapiro, Steven D Pearson. White bagging, brown bagging and site of service policies: best practices in addressing provider markup in the commercial insurance market.Journal of comparative effectiveness research. 2023, 12 (10): e230128
42)- Ramiro Gilardino, Catrin Treharne, Silvy Mardiguian, Sreeram V Ramagopalan. Access in all areas? A round up of developments in market access and health technology assessment: part 1.Journal of comparative effectiveness research. 2023, 12 (10): e230129
43)- Amir Ansaripour, Ann Thompson, Joseph F Styron, Mehdi Javanbakht. Cost-effectiveness analysis of Avance allograft for the treatment of peripheral nerve injuries in the USA.Journal of comparative effectiveness research. 2023, : CER
44)- Peter C Wigfield, Bart Heeg, Mario Ouwens. Improved estimation of overall survival and progression-free survival for state transition modeling.Journal of comparative effectiveness research. 2023, : e230031
45)- Damian M May, Jeffrey Neul, Jesús Eric Piña-Garza, Kalé Kponee-Shovein, Ambika Satija, Malena Mahendran, Nathaniel Downes, Kristy Sheng, Neema Lema, Andra Boca, Patrick Lefebvre, Victor Abler, James M Youakim, Wendy Y Cheng. Gastrointestinal manifestations in pediatric and adult patients with Rett syndrome: an analysis of US claims and physician survey data.Journal of comparative effectiveness research. 2023, : e230054
46)- Eren Watkins, Clifton M Chow, Melissa Lingohr-Smith, Jay Lin, Candice Yong, Krishna Tangirala, Kevin Collins, James Li, Roy Brooks, Jennifer Amico. Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA.Journal of comparative effectiveness research. 2023, : e230079
47)- John J Sheehan, Chris LaVallee, Keshia Maughn, Santosh Balakrishnan, Jacqueline A Pesa, Kruti Joshi, Craig Nelson. Real-world assessment of treatment inertia in the management of patients treated for major depressive disorder in the USA.Journal of comparative effectiveness research. 2023, : e230091
48)- Julia Pisc, Angela Ting, Michelle Skornicki, Omar Sinno, Edward Lee. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data.Journal of comparative effectiveness research. 2023, : e230108
49)- Krithika Rajagopalan, Nazia Rashid, Dilesh Doshi. Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis.Journal of comparative effectiveness research. 2023, : e230114
50)- Alexander Russell-Smith, Louise Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah Webb, Stephanie Dorman, Richa Shah. Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting.Journal of comparative effectiveness research. 2023, : e230142